Mindblown: a blog about philosophy.
-
Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021
View as PDF » BOULDER, Colo.–(BUSINESS WIRE)–Nov. 1, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15. Biodesix’s management will host a conference call and webcast to…
-
Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting
View as PDF » First data from the ORACLE prospective clinical utility study highlights reduction of invasive procedures on patients with benign nodules BOULDER, Colo.–(BUSINESS WIRE)–Oct. 13, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference. Presentations will include newly…
-
Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer
Data highlight the importance of utilizing genomic and proteomic testing for treatment guidance BOULDER, CO, September 15,2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association…
-
Nodify Lung Testing: Blood-Based Biomarker Test for Lung Cancer
If you have been diagnosed with a lung nodule, you might be wondering if it is cancerous, and what happens next. You are not alone. Almost 50% of those who receive chest X-rays or CT scans are told they have a nodule. The good news is that about 95% of nodules turn out to be…
-
Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists
BOULDER, Colo.–(BUSINESS WIRE)–August 24, 2021— Biodesix, Inc. (Nasdaq: BDSX). Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ISO 13485:2016 certification to the Biodesix Laboratory located in DeSoto, Kansas, based on…
-
Biodesix Announces Presentation on Novel Proteomic Techniques in Partnership with Seer
Biodesix and Seer to discuss combined efforts to utilize Seer Proteograph™ Product Suite to drive novel proteomic insights for translational research BOULDER, Colo.–(BUSINESS WIRE)–Jun. 17, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, a webinar to present…
-
Biodesix Announces
Detection of circulating neutralizing antibodies produced in response to COVID-19 vaccination and infection may benefit immunocompromised individuals. BOULDER, Colo. — June 15, 2021— Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a SARS CoV-2 Neutralization Antibody Test (cPass™ Neutralization Test Kit, GenScript Inc.).…
-
Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank
Biodesix intends to make its databank and linked data accessible to research and biopharma partners Boulder, Colorado & San Francisco, California – June 2, 2021 – Biodesix, a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their data. Datavant provides solutions to help…
-
First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker
Study will evaluate the use of a blood-based biomarker to predict outcomes in high PD-L1 expressing non-small cell lung cancer patients treated with immune checkpoint inhibitors plus or minus chemotherapy San Carlos, CA and Boulder, CO, May 26, 2021 – Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease,…
-
Biodesix to Present at the William Blair 41st Annual Growth Stock Conference
BOULDER, Colo. — Apr. 26, 2021– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 2021. William Blair 41st Annual Growth Stock ConferenceDate: Wednesday, June 2, 2021Time: 2:00 PM CT The presentation will…
Got any book recommendations?